Strs Ohio Acquires Shares of 142,516 Agenus Inc. $AGEN

Key Points

• Strs Ohio has acquired 142,516 shares of Agenus Inc. (NASDAQ: AGEN), valued at approximately $214,000, representing 0.52% ownership of the company.
• Institutional investors currently own 61.46% of Agenus' stock, with notable increases in ownership by firms such as Deutsche Bank AG, which raised its position by 538.4%.
• Agenus reported a quarterly earnings miss, with a loss of ($1.00) per share, while the consensus revenue estimate was significantly higher at $49.71 million.

Strs Ohio purchased a new position in shares of Agenus Inc. (NASDAQ:AGEN - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 142,516 shares of the biotechnology company's stock, valued at approximately $214,000. Strs Ohio owned 0.52% of Agenus at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in AGEN. Apollon Wealth Management LLC increased its position in Agenus by 25.0% during the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 5,000 shares in the last quarter. Acadian Asset Management LLC acquired a new position in Agenus during the 1st quarter worth approximately $58,000. Invesco Ltd. acquired a new position in Agenus during the 1st quarter worth approximately $88,000. Charles Schwab Investment Management Inc. increased its position in Agenus by 32.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 63,685 shares of the biotechnology company's stock worth $96,000 after purchasing an additional 15,731 shares in the last quarter. Finally, Deutsche Bank AG increased its position in Agenus by 538.4% during the 4th quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company's stock worth $168,000 after purchasing an additional 51,566 shares in the last quarter. Institutional investors own 61.46% of the company's stock.

Agenus Price Performance

AGEN opened at $4.27 on Thursday. The company's 50-day moving average is $4.90 and its 200 day moving average is $3.94. Agenus Inc. has a fifty-two week low of $1.38 and a fifty-two week high of $7.34. The firm has a market capitalization of $136.04 million, a P/E ratio of -0.60 and a beta of 1.44.

Agenus (NASDAQ:AGEN - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.22). The company had revenue of $25.70 million for the quarter, compared to the consensus estimate of $49.71 million. On average, equities research analysts expect that Agenus Inc. will post -12.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AGEN has been the subject of several recent research reports. Robert W. Baird upped their price target on shares of Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a research report on Wednesday, June 4th. Zacks Research upgraded shares of Agenus to a "hold" rating in a research report on Tuesday, August 12th. Wall Street Zen cut shares of Agenus from a "buy" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, HC Wainwright restated a "buy" rating and issued a $23.00 price target on shares of Agenus in a research report on Wednesday, September 10th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, Agenus currently has a consensus rating of "Moderate Buy" and an average price target of $14.50.

Agenus Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agenus Inc. (NASDAQ:AGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.